ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

11313	Companies
251390	Keywords
180486	Articles
137235	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/03/2026 at 20:19, 5 months 7 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025
OSE Immunotherapeutics publie ses résultats financiers consolidés audités pour l’exercice 2025 et annonce le dépôt de son Document d’Enregistrement Universel 2025

Résultats Financiers Trésorerie Document D’enregistrement Universel OSE Immunotherapeutics Audités
PRESS RELEASE

published on 06/03/2026 at 20:19, 5 months 7 days ago

OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics reports full year 2025 audited consolidated financial results and filing of 2025 Universal Registration Document, confirming cash runway with IRIS Financing

Universal Registration Document OSE Immunotherapeutics Cash Runway 2025 Financial Results IRIS Financing
BRIEF

published on 05/28/2026 at 21:09, 5 months 13 days ago

OSE Immunotherapeutics obtient un financement relais flexible en fonds propres

Plan Stratégique Investisseurs Institutionnels Développement Clinique Émission D'actions Financement Flexible
BRIEF

published on 05/28/2026 at 21:09, 5 months 13 days ago

OSE Immunotherapeutics Secures Flexible Bridge Equity Financing

Strategic Plan Clinical Development Institutional Investors Share Issuance Flexible Financing
PRESS RELEASE

published on 05/28/2026 at 21:04, 5 months 13 days ago

OSE Immunotherapeutics met en place un financement relais flexible en fonds propres
OSE Immunotherapeutics lance un financement relais flexible en fonds propres avec IRIS Capital Investment pour un montant pouvant atteindre 19,3 millions d'euros sur 24 mois, prolongeant ainsi son horizon de trésorerie jusqu'à fin décembre 2026

Financement Fonds Propres OSE Immunotherapeutics Horizon De Trésorerie IRIS Capital Investment
PRESS RELEASE

published on 05/28/2026 at 21:04, 5 months 13 days ago

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics announces a flexible bridge equity financing with IRIS Capital Investment to raise €19.3 million, extending cash runway to December 2026 as part of a global financing strategy

OSE Immunotherapeutics Cash Runway Extension Bridge Equity Financing IRIS Capital Investment Global Financing Strategy
BRIEF

published on 05/22/2026 at 07:35, 5 months 19 days ago

OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

Ovarian Cancer Clinical Trial Results OSE Immunotherapeutics Tedopi® TEDOVA Phase 2
BRIEF

published on 05/22/2026 at 07:35, 5 months 19 days ago

OSE Immunotherapeutics annonce des résultats positifs dans un essai clinique sur le cancer de l'ovaire

Résultats Des Essais Cliniques Tedopi® Immunothérapies OSE Cancer De L'ovaire Phase 2 De TEDOVA
PRESS RELEASE

published on 05/22/2026 at 07:30, 5 months 19 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 6 months 10 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026

Accesswire

Published on 11/10/2026 at 21:00, 53 minutes ago

Golden Minerals Announces Completion of Offering for C$5,000,000
Published on 11/10/2026 at 14:45, 7 hours 8 minutes ago

An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 7 hours 22 minutes ago

First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 7 hours 23 minutes ago

Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 7 hours 23 minutes ago

ACCESS Newswire Reports Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/10/2026 at 21:24, 29 minutes ago

EQS-Adhoc: Kapsch TrafficCom AG:
Published on 11/10/2026 at 21:18, 35 minutes ago

ARYZTA director steps down
Published on 11/10/2026 at 19:21, 2 hours 32 minutes ago

ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 2 hours 58 minutes ago

REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 3 hours 8 minutes ago

Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications

Les Echos

Published on 11/10/2026 at 18:00, 3 hours 53 minutes ago

Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 4 hours 8 minutes ago

Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:40, 4 hours 13 minutes ago

Production du 3ième trimestre 2026
Published on 11/10/2026 at 17:35, 4 hours 18 minutes ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 4 hours 22 minutes ago

CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.

View all LES ECHOS COMFI WIRE